Drugs / PVSRIPO
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03564782 | Jun 2019 → Apr 2022 | invasive breast carcinoma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04125719 | Jun 2020 → Oct 2024 | melanoma | Darell Bigner | Withdrawn | No outcome recorded |
| Phase 1 | NCT03712358 | Nov 2018 → Mar 2021 | melanoma | Istari Oncology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01491893 | Apr 2012 → Jun 2017 | glioblastoma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03973879 | Feb 2020 → Jan 2024 | malignant glioma | Darell Bigner | Withdrawn | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04599647 | — | glioblastoma | Istari Oncology, Inc. | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVSRIPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712358 ↗ |
| Modality | Other / unclassified | “PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera” PMID 33875611 ↗ Apr 2021 |
| Route | Other | “intratumoral infusion of PVSRIPO” PMID 29943666 ↗ Jun 2018 |